Exact Sciences (EXAS) Tops Q1 EPS by 9c, Offers FY Guidance

Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.32), $0.09 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $48.4 million versus the consensus estimate of $37.29 million.

GUIDANCE:

Exact Sciences sees FY2017 revenue of $195-205 million, versus the consensus of $178 million.

• The company anticipates revenue of $195-205 million and completed Cologuard test volume of at least 470,000 tests during 2017. Previous guidance was $170-180 million in revenue and at least 415,000 completed Cologuard tests. For the second quarter, the company anticipates at least 115,000 completed Cologuard tests.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• NVE Corporation names new CEO and expands board to seven members
• C.H. Robinson acquires DeSpir Logistics for $75 million